Pfizer Inc.

PFE

US7170811035

Pharmaceuticals

Market Closed - NYSE Other stock markets 04:05:03 2026-06-11 pm EDT			After hours 08:00:00 pm
26.17 ^USD	+2.23%		26.20	+0.11%

Jun. 11	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
Jun. 11	Race to launch weight-loss pill heats up as Novo wins UK approval	RE

Pfizer CEO Bourla to Meet Activist Investor Starboard Value Next Week, FT Reports

Published on 10/08/2024 at 03:29 pm EDT - Modified on 10/08/2024 at 05:30 pm EDT

Dow Jones

PFIZER INC.

+2.23%

--Pfizer's Chief Executive Albert Bourla plans to meet Starboard Value next week with at least one other director after the activist investor acquired a $1 billion stake in the healthcare company, the Financial Times reports, citing sources.

--The planned meeting shows Starboard's demands are getting a hearing at the highest levels of the company, the FT reports.

--Starboard's exact recommendations couldn't be ascertained and the firm declined to comment, the FT reports, adding that Pfizer didn't immediately respond to a request for comment.

Full article at https://www.ft.com/content/38a73294-f6b0-48c8-a29a-8626c2da30d5

Write to Sabela Ojea at sabela.ojea@wsj.com.

(END) Dow Jones Newswires

10-08-24 1729ET

Latest news about Pfizer Inc.

Jun. 11	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
Jun. 11	Race to launch weight-loss pill heats up as Novo wins UK approval	RE
Jun. 11	Commission's appeal against COVID vaccine contract disclosures should be dismissed, court adviser says	RE
Jun. 11	Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal	RE
Jun. 10	Pfizer's Risk-Reward More Balanced Ahead of 2 Key Pipeline Catalysts, RBC Capital Markets Says	MT
Jun. 10	Pfizer CEO warns German investment at risk over drug pricing policies	RE
Jun. 10	Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon	RE
Jun. 10	Analyst recommendations: Nike, Pfizer, Hewlett Packard, Intel, The Trade Desk…
Jun. 10	RBC Upgrades Pfizer to Sector Perform from Underperform, PT is $25	MT
Jun. 09	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
Jun. 08	AstraZeneca's Obesity Pill Helps Patients Lose Weight in Midstage Trials	DJ
Jun. 08	Pfizer Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 08:00 AM
Jun. 08	Markets Ask AI for Receipts
Jun. 08	U.S. FDA Approves Pfizer?s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need	CI
Jun. 08	Pfizer Gets FDA Expanded Hympavzi Approval	DJ

Albert Bourla

Albert Bourla is Chairman, Chief Executive & Operating Officer at Pfizer Inc., Member of The Business Roundtable and Member of The Business Council and on the board of 7 other companies. Dr. Bourla received a doctorate from School of Veterinary Medicine (Greece).

View full profile

Chart Pfizer Inc.

Duration

Period

PFE: Dynamic Chart

Company Profile

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (47.4%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (26.2%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (24.5%); - other (1.9%). The United States accounts for 60.8% of net sales.

Employees

75,000

Sector

Pharmaceuticals

More about the company